Alector saw the highest growth of 0.82% in patent filings and 2.49% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.66% and grants by 0.66%. GlobalData’s DataBook provides a comprehensive analysis of Alector‘s patent filings and grants. Buy the databook here.
Alector has been focused on protecting inventions in United States(US) with seven publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 25% filings and 44% grants. The European Patent Office(EPO), United States(US), Japan(JP), and World Intellectual Property Organization(WIPO) patent Office are among the top ten patent offices where Alector is filings its patents. Among the top granted patent authorities, Alector has 44% of its grants in United States(US) and 44% in Japan(JP).
Regeneron Pharmaceuticals and Amgen could be the strongest competitors for Alector
Patents related to rare diseases and genomics lead Alector's portfolio
Alector has the highest number of patents in rare diseases followed by, genomics and Covid-19. For rare diseases, nearly 62% of patents were filed and 57% of patents were granted in Q2 2024.
Alzheimer's disease related patents lead Alector portfolio followed by injury, and frontotemporal dementia with parkinsonism-17 (ftdp-17)
Alector has highest number of patents in alzheimer's disease followed by injury, frontotemporal dementia with parkinsonism-17 (ftdp-17), dementia, and sporadic inclusion body myositis (s-ibm). For alzheimer's disease, nearly 11% of patents were filed and 2% of patents were granted in Q2 2024.
For comprehensive analysis of Alector's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.